Skip to content
logologologo
  • Home
  • About
    • About AKSAM
    • Our Team
    • Contacts
    • Become A Member
  • AKSAM NEWS
  • Provider Locator
  • AKSAM Events
  • Resources
    • Guidelines and Publications
    • Education
    • DEA Education Requirements
    • PCSS SUD 101 Core Curriculum
    • Chronic Pain Core Curriculum
    • Legislation and Advocacy
  • Members
    • Login
    • My AKSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Add My Practice to Physician Locator
logologologo
  • Home
  • About
    • About AKSAM
    • Our Team
    • Contacts
    • Become A Member
  • AKSAM NEWS
  • Provider Locator
  • AKSAM Events
  • Resources
    • Guidelines and Publications
    • Education
    • DEA Education Requirements
    • PCSS SUD 101 Core Curriculum
    • Chronic Pain Core Curriculum
    • Legislation and Advocacy
  • Members
    • Login
    • My AKSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Add My Practice to Physician Locator
  • Home
  • About
    • About AKSAM
    • Our Team
    • Contacts
    • Become A Member
  • AKSAM NEWS
  • Provider Locator
  • AKSAM Events
  • Resources
    • Guidelines and Publications
    • Education
    • DEA Education Requirements
    • PCSS SUD 101 Core Curriculum
    • Chronic Pain Core Curriculum
    • Legislation and Advocacy
  • Members
    • Login
    • My AKSAM Account
    • Members Roster
    • Member Events
    • Chapter Meetings Minutes & Agendas
    • Member’s Only Discussions
    • Chapter Documents
      • ASAM Chapter Affiliation Agreement
      • ASAM Chapter Agreement
      • Constitution and Bylaws
    • Add My Practice to Physician Locator
Updates to rules for Opioid Treatment Programs: The 42 CFR Part 8 Final Rule Table of Changes
Guidelines and Publications National Advocacy and Legislation
0
0
February 21, 2025

Updates to rules for Opioid Treatment Programs: The 42 CFR Part 8 Final Rule Table of Changes

The following table summarizes some key changes to 42 CFR part 8. This table does not discuss all changes. To review all of the changes to 42 CFR part 8, interested parties are encouraged to view the final rule.

For questions regarding implementation of the final rule, please contact SAMHSA’s Division of Pharmacologic Therapies at 240-276-2700 or DPT@samhsa.hhs.gov or your State Opioid Treatment Authorities.

Provision What Changed? Why Has This Changed?
Title and Terminology The title of the rule has been updated to “Medications for the Treatment of Opioid Use Disorder.” The final rule replaces outdated terms such as “detoxification” and adds new definitions. Aligns with current evidence-based practices and terminology to promote patient-centered treatment activities.
Admissions The final rule eliminates the 1-year opioid addiction history requirement and promotes priority treatment for pregnant individuals. It also removes the requirement for two documented instances of unsuccessful treatment for people under age 18. Allows consent to be obtained electronically. In addition, medication access is no longer contingent on receipt of counseling. The final rule also allows screening examinations to be performed by practitioners external to the OTP under certain conditions. Removes unnecessary barriers to medication access by focusing on individual patient needs. Adds protections for vulnerable groups.
Treatment Standards The final rule adds patient-provider “shared decision making” considerations to all care plans and incorporates harm reduction principles into treatment. Recognizes the need to meet patients where they are with their opioid and other substance use disorders, and help patients make positive change, reducing harm along the way.
Take-Home Doses The final rule updates criteria for consideration of take-home doses of methadone and allows patients to receive take-home doses from the first week of treatment under certain conditions. Safeguards like diversion control procedures remain. Makes permanent the COVID-19 flexibilities which demonstrated that wider access to methadone improves outcomes, without increasing rates of diversion, when paired with individualized, clinical judgment, safeguards, and patient education.
Telehealth The final rule allows screening patients for initiation of buprenorphine via audio-only or audio-visual telehealth technology if certain providers determine that an adequate evaluation of the patient can, or has been, completed via telehealth. The final rule also allows for screening patients for the initiation of methadone via audio-visual telehealth under certain conditions. Telehealth is an evidence-based practice that has been shown to be safe and effective. Its use expands access to care and promotes activities known to support recovery such as employment.
Interim Treatment Interim Treatment is now allowed at any qualifying OTP and the time frame for Interim Treatment was expanded from 120 to 180 days. Requires prioritization of moving patients from interim into comprehensive treatment. State approval for use of interim treatment is still required. Expands access to treatment.
Accreditation Body Oversight The responsibilities of Accrediting Bodies are clarified in terms of reporting time frames, follow-up on OTP implementation of corrective measures and communications with SAMHSA. Improves monitoring to uphold quality standards at OTPs.
OTP Compliance and Accreditation The final rule sets forth time frames and follow-up of OTPs on corrective measures. The time for OTPs to take corrective action is extended to 180 days following receipt of the survey report. Removes an expired type of accreditation, clarifies the category of “provisional” certification and authorizes “conditional” certification. Allows continuity of operations if compliance issues arise while restoring full standards.
Scope of Practice Expansion Allows nurse practitioners and physician assistants to order MOUD for dispensing at the OTP if consistent with state law. The final rule also clarifies medication unit rules and defines the range of services that they may offer. Establishes flexibility for practitioner staffing to improve access, especially in underserved areas. Clarifies the scope of medication units that can reach new areas.
adweb.admin
Author: adweb.admin

Nick Covanes is the C.E.O. and Creative Director of Adwebvertising, LLC and has been a leader in the industry since 2011. Nick is experienced in all facets of digital marketing and provides this experience to individual businesses and organizations to help them realize their full growth potential.

Share

Post navigation

Prev
Next

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

The Alaska Society of Addiction Medicine 

Social Media

Instagram Link

Recent Posts

  • What Readers Can Expect from the Alaska MAT Guide – Third Edition July 15, 2025
  • New Virtual CME Series Launching for Alaska Providers April 15, 2025

Quick News

Another Brilliant Design by: Adwebvertising…It’s Like Advertising…Only Better!

Copyright © 2023, Alaska Society of Addiction Medicine. All Rights Reserved